DIRS.INFO The most relevant business & tech news

Eli Lilly also is expected to present data on another weight-loss drug called orforglipron, which patients take orally instead of through an injection. Retatrutide, Mounjaro and weight-loss drug Wegovy, produced by rival Novo Nordisk (NVO), are all injectable. But if the data were to fall short of expectations, the analysts don't foresee much downside to J & J shares. However, with JNJ-2113, Morgan Stanley noted that J & J management has touted its efficacy profile "without the baggage of a JAK label." J & J has consistently denied those accusations.

Persons: Eli Lilly, Johnson, Morgan Stanley —, Eli Lilly Eli Lilly, Morgan Stanley, Eli Lilly's Mounjaro, Mounjaro, Lilly's, retatrutide, hasn't, haven't, Jim Cramer's, Jim Cramer, Jim, AJ Mast Organizations: American Diabetes Association, Novo Nordisk, U.S . Food, Drug Administration, Pfizer, Novo Nordisk's, Johnson, American Academy of Dermatology, topline, J's, LTL Management, CNBC, Bloomberg, Getty, & ' $ Locations: U.S, Novo, Indianapolis , Indiana

☆ An investment chief who manages $1 billion in assets shares 10 investments that will reduce your portfolio's volatility while this bear market lasts longer than expected.
▼ + stars: | 2023-05-03 | by ( James Faris | ) www.businessinsider.com time to read: +5 min

Here are 10 ways to protect against losses and volatility in this long-lasting bear market. "It went beyond dodging a bullet," Steve Sosnick, the chief strategist at Interactive Brokers, said of first quarter earnings results in a late April interview with Insider. Weaker earnings raise valuation concernsBut some investors aren't impressed by Q1 earnings — at least not enough to get bullish. Besides weaker earnings growth and lofty valuations, another risk for stocks is that upcoming quarterly results will miss higher expectations in a shaky economy. "We're still looking at fairly high-single-digit earnings growth for the next couple of quarters overall," Sosnick said.

☆ A solid start to earnings season will be put to the test in the week ahead
▼ + stars: | 2023-04-29 | by ( Zev Fima | ) www.cnbc.com time to read: +14 min

The biggest week of this earnings season showed us that things aren't as bad as many feared. The week ahead of earnings, including several more Club names, should tell us more. The results are always important, but it's the guidance and management commentary we will really hone in on to better understand the path ahead. In Amazon's case, a solid first quarter for its AWS cloud business was overshadowed by management seeing a material slowdown in April. ET: Nonfarm Payrolls Looking back It was the biggest week of this earnings season for the Club as several of our mega-cap holdings and industry bellwethers reported results.

☆ This weight-loss drug maker's stock is up 20% this year — and Barclays sees it going higher
▼ + stars: | 2023-04-28 | by ( Ganesh Rao | ) www.cnbc.com time to read: +3 min

Wegovy catapulted into the spotlight thanks to its success in weight loss and the endorsement by celebrities and social media influencers, including Tesla CEO Elon Musk. However, some investors are concerned that Novo's stock has already factored in this growth potential, as its shares have risen by 137% since the U.S. Food and Drug Administration approved the drug in June 2021. Novo's shares are also traded in New York Stock, London , and Frankfurt. NVO 5Y mountain According to Barclays' Field, the market for obesity treatment drugs could be worth as much as $200 billion within the next decade. "So does the weight loss that comes with taking Wegovy prevent you from having a heart attack or a stroke among those that have a higher risk?

☆ Credit Suisse upgrades Novo Nordisk on 'surprise' growth of obesity and diabetes drugs Ozempic and Wegovy
▼ + stars: | 2023-04-13 | by ( Michelle Fox | ) www.cnbc.com time to read: +2 min

Credit Suisse upgraded Danish pharmaceutical company Novo Nordisk to outperform from neutral on Thursday, citing growth in its obesity and diabetes drugs. "Rx trends for both Ozempic and Wegovy YTD have been a major surprise and have significantly outperformed our expectations," he wrote. Now that Wegovy is back in supply, Credit Suisse had expected a potential slowdown in growth for Ozempic. Instead, while there has been a rise in new patients taking Wegovy, Ozempic is continuing to see growth, Dunn said. "Novo sees growth being driven by penetration in diabetes rather than off-label obesity use, which is backed up by the fact the Ozempic growth has accelerated despite re-supply of Wegovy for Obesity," he said.

☆ A flurry of news outside the portfolio has implications for 3 of our stocks
▼ + stars: | 2023-04-13 | by ( Jeff Marks | ) www.cnbc.com time to read: +7 min

Here are three noteworthy news developments over the past two days, which contain useful insights about our stocks. For the full year 2023, Novo now expects sales growth in the range of 24% and 30%, compared to prior estimates of 13% to 19%. In addition, operating profit growth is expected to be in the range of 28% and 34%, up from a prior range of 13% to 19%. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

☆ Morgan Stanley's case for six Club names, including Alphabet and Microsoft
▼ + stars: | 2023-03-21 | by ( Paulina Likos | ) www.cnbc.com time to read: +6 min

In a research note Tuesday, Morgan Stanley identified its "best long-term picks" for 2025, in line with our approach for assessing companies. Six names on Morgan Stanley's list were Club holdings, all of which the firm rated a buy. Alphabet (GOOGL): Morgan Stanley analysts think artificial intelligence (AI) will create a new growth opportunities at Google parent Alphabet in its core products, including its search engine, YouTube and cloud offerings. Morgan Stanley has price target of of $135 per share on the stock. Eli Lilly (LLY): The pharmaceuticals giant is well-positioned within the U.S. due to its strong pipeline of drugs and "robust new product cycles," Morgan Stanley analysts argued.

☆ Jim Cramer's Investing Club meeting Friday: Costco, Eli Lilly, Apple
▼ + stars: | 2023-03-03 | by ( Paulina Likos | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Stick with Costco Watch Eli Lilly Own Apple 1. Morgan Stanley predicted the results could lead to a 5% to 10% upside for both Novo and Eli Lilly shares. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER .

☆ Sell biopharma stock Amgen ahead of its obesity drug update, Barclays says
▼ + stars: | 2022-10-31 | by ( Sarah Min | ) www.cnbc.com time to read: +2 min

Investors should sell biopharma stock Amgen ahead of its obesity drug update next week, according to Barclays. Analyst Carter Gould downgraded Amgen to underweight from equal weight, saying there are high expectations around its obesity drug AMG133 after the stock's rally this month. Amgen shares outperformed nearly all its peers this month, even companies that have reported strong third-quarter results, after announcing at the start of October that it will disclose more obesity drug data, according to Barclays. In short, we think AMGN shares could come under pressure after the recent gains on the back of this update," the analyst wrote. The analyst's $234 price target represents 14.5% downside from where Amgen shares closed Friday at $273.81.

Search resuls for: "NVO"

9 mentions found